|
covid-19 |
20 |
|
influenza |
14 |
|
serology |
10 |
|
adult |
9 |
|
sars-cov-2 |
9 |
|
antibody |
8 |
|
cd8+ t cells |
6 |
|
clade 2.3.4.4.b |
6 |
|
coronavirus |
6 |
|
cross-reactive antibody response |
6 |
|
hla-b*15:01 |
6 |
|
influenza a(h1n1)pdm09 |
6 |
|
influenza a(h5n1) |
6 |
|
influenza virus |
6 |
|
neuraminidase inhibition antibody |
6 |
|
neutralization |
6 |
|
pandemic risk assessment |
6 |
|
peg precipitation |
6 |
|
respiratory infections |
6 |
|
rt-qpcr |
6 |
|
sars coronavirus 2 |
6 |
|
seroepidemiology |
6 |
|
severe disease |
6 |
|
t cell receptors |
6 |
|
virus outbreak |
6 |
|
viruses |
6 |
|
wastewater surveillance |
6 |
|
anxiety disorder |
5 |
|
checklist |
5 |
|
civil disorder |
5 |
|
cohort analysis |
5 |
|
epidemiology |
5 |
|
mpox virus |
5 |
|
norovirus |
5 |
|
rotavirus |
5 |
|
adcc |
4 |
|
adolescent |
4 |
|
aged |
4 |
|
antibody titerarticleblood donor |
4 |
|
cervical cancer screening |
4 |
|
colonoscopy |
4 |
|
cost-effectiveness analysis |
4 |
|
d614g |
4 |
|
fitness |
4 |
|
gastroscopy |
4 |
|
hpv vaccination |
4 |
|
immunopersistence |
4 |
|
ipv |
4 |
|
mutation |
4 |
|
n-ctd |
4 |
|
natural infection |
4 |
|
nk cells |
4 |
|
opv |
4 |
|
orf8 |
4 |
|
polio |
4 |
|
population-based screening program |
4 |
|
sars-cov |
4 |
|
staging |
4 |
|
vaccine |
4 |
|
vaccine induced immunity |
4 |
|
adverse weather |
3 |
|
blood donation |
3 |
|
blood inventory |
3 |
|
china |
3 |
|
commodity hardware |
3 |
|
cost analysis |
3 |
|
donor |
3 |
|
effective reproduction number |
3 |
|
human behaviour |
3 |
|
infectiousness |
3 |
|
information extraction |
3 |
|
large language models |
3 |
|
local travel behaviour |
3 |
|
lupus nephritis |
3 |
|
offline |
3 |
|
prompt strategy |
3 |
|
public transport |
3 |
|
renal biopsy reports |
3 |
|
respiratory infection |
3 |
|
school closure |
3 |
|
subway |
3 |
|
susceptibility |
3 |
|
temperature |
3 |
|
acute lower respiratory infection |
2 |
|
bivalent vaccine |
2 |
|
coronavirus disease 2019 |
2 |
|
cost-effectiveness |
2 |
|
coxsackievirus a16 |
2 |
|
decision making |
2 |
|
enterovirus 71 |
2 |
|
epidemic size |
2 |
|
global health |
2 |
|
h1n1 influenza - china - hong kong - epidemiology. |
2 |
|
hand, foot and mouth disease |
2 |
|
health policy |
2 |
|
influenza - transmission |
2 |
|
maternal immunisation |
2 |
|
mers |
2 |
|
middle east respiratory syndrome |
2 |
|
monoclonal antibody |
2 |
|
paediatric immunisation |
2 |
|
public health |
2 |
|
respiratory syncytial virus |
2 |
|
sars |
2 |
|
severe acute respiratory syndrome |
2 |
|
sse |
2 |
|
superspreading event |
2 |
|
africa |
1 |
|
african countries |
1 |
|
baseline data |
1 |
|
behaviour |
1 |
|
behaviours |
1 |
|
communication |
1 |
|
congenital rubella syndrome |
1 |
|
economic evaluation |
1 |
|
epi |
1 |
|
factor analysis |
1 |
|
health risk perception |
1 |
|
immunization |
1 |
|
ivir-ac |
1 |
|
linear regression |
1 |
|
malaria |
1 |
|
media use |
1 |
|
meta-analysis |
1 |
|
omicron |
1 |
|
polychoric |
1 |
|
precautionary |
1 |
|
predict |
1 |
|
predictability |
1 |
|
prediction |
1 |
|
predicts |
1 |
|
preventive |
1 |
|
propensity |
1 |
|
protective |
1 |
|
protective behavior |
1 |
|
rcv |
1 |
|
rubella |
1 |
|
social vulnerability |
1 |
|
social vulnerability index |
1 |
|
sociodemographic |
1 |
|
socioeconomic |
1 |
|
varimax rotation |
1 |
|
western countries |
1 |
|
western pacific |
1 |
|
who |
1 |
